Skip to contentM
Myriad Genetics Inc
M
MYGNMyriad Genetics Inc Source filing unavailable
Q3 2014 · —
Revenue$182.92M$182.92M+16.9% vs Q3 2013 Net Income$36.77M$36.77M−3.0% vs Q3 2013 EPS Diluted$0.48$0.48+4.3% vs Q3 2013 Operating Income$55,287,000−4.5% Operating Cash Flowderived$11,249,000−69.9% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
Free Cash Flowderived
Margins · derivedOperating margin30.2%−6.8 pt vs Q3 2013
Net margin20.1%−4.1 pt vs Q3 2013